University of Illinois Chicago is one of the U.S. sites participating in clinical trials to cure severe red blood congenital diseases such as sickle cell anemia or Thalassemia by safely modifying the DNA of patients’ blood cells.
A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.
DALLAS – Jan. 13, 2021 – A new treatment that combines two existing medications may provide long-sought relief for many battling debilitating methamphetamine use disorder, according to a study to be published tomorrow in The New England Journal of Medicine.
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center published promising findings today in the New England Journal of Medicine on preventing a common complication to lifesaving blood stem cell transplantation in leukemia.
Many individuals with COVID-19 say they experience headaches, along with a “fuzziness” or brain fog that can persist for weeks or months following recovery from the acute respiratory symptoms. This is sometimes referred to as “COVID brain.” The long-term clinical implications of infection by the virus continue to baffle scientists and, until now, the neurological manifestations have been believed to be a result of direct damage to nerve cells. However, a new study in the New England Journal of Medicine suggests the virus might actually damage the brain’s small blood vessels rather than nerve cells, themselves.
As the first doses of COVID-19 vaccines are being rolled out, it is still unclear whether enough Americans are willing to be vaccinated to allow the nation to return to normalcy.
Antibiotics may be a good treatment choice for some appendicitis patients, according to early results from the Comparing Outcomes of antibiotic Drugs and Appendectomy (CODA) trial reported in the New England Journal of Medicine.
Hearing experts advocate in The New England Journal of Medicine for the FDA to implement the Over-the-Counter Hearing Aid Act of 2017. The FDA missed the deadline to release the much-anticipated regulations on August 18, 2020
For many of us, this year’s holiday season may look different, and many are asking how we can enjoy the fellowship of the season while keeping ourselves, our loved ones and our communities safe from COVID-19.
Cleveland: Cleveland Clinic researchers leading a global clinical trial have found that rilonacept, an FDA approved drug for other inflammatory diseases, resolved acute pericarditis episodes and reduced risk of pericarditis recurrence. The study was published today in the New England Journal of Medicine and presented at the American Heart Association’s Scientific Sessions.
Cleveland: Cleveland Clinic researchers have found that cryoballoon ablation as the initial treatment for atrial fibrillation is more effective than current standard-of-care management using medications. The study was published today in the New England Journal of Medicine.
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol—the so-called “bad” cholesterol—by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found.
The information came from the International Polycap Study 3 (TIPS-3) study which followed the participants an average of 4.6 years. The study of 5,714 people from nine countries, particularly India and the Philippines, looked at the polypill alone compared to a placebo; aspirin alone versus a placebo, and the polypill plus aspirin versus a double placebo. The men in the study were 50 or older and the women were 55 or older.
Three medical authors published a clinical decisions article in the New England Journal of Medicine documenting three approaches to managing elective surgery during COVID-19 given the same scenario.
COVID-19 (coronavirus) patients who were administered a novel antibody had fewer symptoms and were less likely to require hospitalization or emergency medical care than those who did not receive the antibody, according to a new study published in the The New England Journal of Medicine.
Patients with diabetic kidney disease can potentially be treated with a new investigational medication that may slow the progress of their illness without harmful side effects to their hearts, according to the results of a global clinical trial announced Friday.
The drug tocilizumab (Actemra) does not reduce the need for breathing assistance with mechanical ventilation or prevent death in moderately ill hospitalized patients with COVID-19, according to a new study led by researchers at Massachusetts General Hospital (MGH).
Immediate actions are needed to limit the greenhouse gas emissions that are driving climate change that helps fuel wildfires, a Monash University study says.
Michigan Medicine participated in a large clinical trial which found that, in many cases, appendicitis can be safely and effectively treated with antibiotics instead of surgery.
Every year more than 250,000 people undergo surgery for appendicitis, making it one of the 20 most common surgeries performed in the United States.
In the largest randomized U.S. study of appendicitis published today in the New England Journal of Medicine, researchers from Henry Ford Health System and 24 other sites around the U.S. report that seven in 10 patients who received antibiotics avoided surgery and that patients who took antibiotics for symptom relief fared no worse in the short term than those who underwent surgery.
Results of a first-of-its-kind clinical trial shed light on when antibiotics instead of surgery might be the better choice for treating appendicitis in some patients, according to results from the national Comparing Outcomes of Antibiotic Drugs and Appendectomy (CODA) trial published today in the New England Journal of Medicine.
Seven of 10 adults with appendicitis can safely avoid surgical removal of their appendix (appendectomy) for at least several months by receiving a course of antibiotics.
Antibiotics may be a good choice for some, but not all, patients with appendicitis, according to results from the Comparing Outcomes of Drugs and Appendectomy (CODA) trial.
The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer, according to a new study led by Yale Cancer Center researchers.
A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults.
According to updated findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.
For patients with advanced solid cancers and KRAS G12C mutations, the targeted therapy sotorasib, a KRAS G12C inhibitor, resulted in manageable toxicities and durable clinical benefits, particularly in lung and colorectal cancer, in Phase I study
UNC School of Medicine researchers took striking images of the SARS-CoV-2 virus produced by infected respiratory epithelial cells inside human respiratory tract cultures. The New England Journal of Medicine featured this work in its “Images in Medicine” section.
New findings show that some patients with a rare and aggressive form of leukodystrophy may benefit from receiving treatment with a class of targeted therapy drugs that could improve their neurological function.
DALLAS – Aug. 31, 2020 – Three anticonvulsant drugs commonly used to stop prolonged, potentially deadly seizures each work equally well, according to a national study led by physicians at UT Southwestern. The results provide reassurance to patients who may have drug allergies and to physicians and hospitals that may not have supplies of all three.
An artificial pancreas originally developed at the University of Virginia Center for Diabetes Technology safely and effectively manages blood sugar levels in children ages 6 to 13 with type 1 diabetes, a national clinical trial has found.
For patients with non-small cell lung cancers marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of patients in a Phase I/II trial.
A longstanding theory has suggested that gastric bypass surgery may have unique, weight loss-independent effects in treating type 2 diabetes. But new research from Washington University School of Medicine in St. Louis indicates that weight loss after surgery, rather than the surgery itself, drives metabolic improvements, such as the remission of diabetes.
The enzyme serine palmitoyl-transferase can be used as a metabolically responsive “switch” that decreases tumor growth, according to a new study by a team of San Diego scientists, who published their findings Aug. 12 in the journal Nature.
By restricting the dietary amino acids serine and glycine, or pharmacologically targeting the serine synthesis enzyme phosphoglycerate dehydrogenase, the team induced tumor cells to produce a toxic lipid that slows cancer progression in mice.
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.
The U.S. Food and Drug Administration granted accelerated approval for brexucabtagene autoleucel (TECARTUS™, formerly KTE-X19) as the first and only CAR T-cell therapy for patients with mantle cell lymphoma (MCL) relapsed or refractory to prior treatments. Investigators from Hackensack Meridian John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey participated in the pivotal trial which the approval was based: the ZUMA-2 clinical trial, which assessed the safety and effectiveness of brexucabtagene autoleucel in patients with relapsed or refractory MCL who had received up to five prior regimens of treatment and had exhausted all other therapies. That transformative study showed that 93% of patients responded to treatment, with 67% achieving a complete response (no evidence of disease). The data were published in the April 2, 2020 issue of the New England Journal of Medicine.
Authors of a new perspective on health inequities say that, in addition to health policy and individual-level efforts, social policy solutions are needed. They identify two key lessons from the pandemic: public policy enables public health and health equity requires big investments in public policy.
A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 — the virus that causes the disease — drop sharply over the first three months after infection, decreasing by roughly half every 36 days on average. If sustained at that rate, the antibodies would disappear within about a year.
A just published survey of more than 1,300 U.S. cataract surgeons and nurses shows 93 percent believe that something needs to be done to reduce the excessive amount of waste produced by surgery.
A clinical trial conducted at Washington University School of Medicine in St. Louis and other sites has found evidence that the experimental drug tofersen lowers levels of a disease-causing protein in people with an inherited form of amyotrophic lateral sclerosis, or ALS, caused by mutations in the gene SOD1.
Rutgers pediatricians co-lead first nationwide study describing the diagnosis, treatments and outcomes of COVID-19 related multiple inflammatory syndrome in children